Bio-Rad stock looks undervalued, boosted by its Sartorius stake, but headwinds and volatile guidance cap upside. Click here ...

The global DNA methylation market size was valued at US$ 1.9 Bn in 2025 and is projected to reach US$ 7.7 Bn by 2036, growing ...

Jan 6 : ‌Variant Bio, a private biotech firm, said on Tuesday it has launched a platform that uses artificial intelligence on genetic data to discover new drug candidates to send into human trials.

Boehringer Ingelheim has unveiled its second kidney-focused collaboration in recent weeks, this time penning a deal worth over $120 million biobucks with genomics-focused Variant Bio. The alliance ...

SEATTLE, Jan. 6, 2026 /PRNewswire/ -- Variant Bio, a genomics-driven AI drug discovery company, today announced the launch of Inference, the world's first agentic genomic drug discovery platform.

Background: While treatment algorithms for the most common forms of monogenic diabetes (MD) are well established, managing affected pregnancies remains a clinical challenge. This study aimed to ...

The market didn't react positively to the diagnostics specialist's third-quarter earnings report. It beat on both the top and bottom lines, but growth rates were low. Bio-Rad's Q3 saw the company book ...

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Bio-Rad Laboratories ( (BIO)) has ...